Chi is responsible for the development of Patient Focused Medicines Development (PFMD) and IMI-PARADIGM initiatives. Together with the team, Chi drives co-creation activities, connects and engages with stakeholders within and beyond the PFMD network, and coordinates sub-projects within both initiatives, bringing collaborative leadership to build methodologies and tools and make patient engagement happen on collective platforms (with more than 90 member organizations combined). Chi has a Master degree in International Relations from the University of Southern Denmark and a Bachelor degree in Business Administration from Haaga-Helia, University of Applied Sciences, in Finland. Her past work has enabled her to gain experience in collaborating with partners from various backgrounds and expertise, as well as working with large volunteer groups innovating with them in delivering focused outcomes like inspiring events to an audience of hundreds.
Organizations
The Synergist runs programmes aimed at solving challenges which others ignore or have been unable to resolve. Our approach is a bit different. We’re not issue experts. We focus primarily on bringing the most important stakeholders together and building shared value, rather than trying to do it all ourselves. Given the complexity of the world we live in and the challenges we face, we’re convinced there is no better way.
The Patient Focused Medicines Development (PFMD) group, established in 2015, is an independent multinational coalition, managed in collaboration with The Synergist. Its goal is to bring together initiatives and best practices that integrate the voice of the patient throughout the lifecycle of medicines development, thereby speeding up the creation and implementation of an effective, globally standardized framework. PFMD seeks to have a balanced representation of stakeholders to ensure transparency, inclusiveness, and credibility. Stakeholders include patients and patient organizations across diverse areas of health and industry. We also intend to invite regulators, payers and other professional organizations to the global group to ensure diversity of perspectives.
Initiatives (19)
PE Stakeholder Expectation Matrix
SYNaPsE Patient Engagement Global Landscape, Expert Network and Repository
Co-creation of the Patient Engagement "Meta-Framework"
150+ PE activities to inform PE Quality Guidance's how to modules
How-to guide for patient engagement in the early discovery and preclinical phases
Events (5)
18
19
PE Open Forum 2019
13
14
1st Asia-Pacific Patients Congres
15
15
PFMD Board Meeting
04
04
High Impact Virtual Engagements webinar series | Episode 1
05
05
High Impact Virtual Engagements webinar series | Episode 3
Resources (13)
Co-creation of patient engagement quality guidance for medicines development: an international multistakeholder initiative
07 Mar 2019
WORKSHOP 1 How to engage patients in early development and preclinical phases of medicines development
23 Sep 2019
PE Open Forum Conference Report 2019
07 Nov 2019 Other
D1.1 Survey analysis report on stakeholder-specific preferences, needs and expectations
08 Nov 2019 Research report
Working Group Updates 2020
11 Mar 2020 Framework/guidance
If Medicines Could Talk- Patient Focused Medicines Development - Early Stage Patient Engagement
16 Oct 2020 Podcast
High Impact Virtual Engagements Webinar Series | Episode 1 recording
12 Jan 2021 Learning and training
High Impact Virtual Engagements Webinar Series | Episode 2 recording
28 Jan 2021 Learning and training
Commitments (2)
Project Manager
I will find a patient and spend time with them in the next 6 months to learn about how I can take their needs into consideration more in my role when I arrange meetings that involve patients.
Completed
Project Manager
I will take my learnings from listening to patients and improve my communication with patients that are involved with PFMD work streams; to take their needs as much as possible into account with the content and timing of the communications.
Completed